Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06238843
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 378
- Registration Number
- NCT06212752
- Locations
- 🇯🇵
Miyagi Cancer Center ( Site 4401), Natori, Miyagi, Japan
🇯🇵Fujita Health University ( Site 4406), Toyoake, Aichi, Japan
🇯🇵Kurume University Hospital ( Site 4412), Kurume, Fukuoka, Japan
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06207305
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Drug Screening Using IMD in Bladder Cancer
- Conditions
- Interventions
- Device: Implantable Micro-DeviceDrug: MethotrexateDrug: CarboplatinDrug: AvelumabDrug: PaclitaxelDrug: VinblastineDrug: Gemcitabine/Cisplatin IDrug: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/AvelumabDrug: Gemcitabine/Cisplatin IIDrug: CisplatinDrug: NivolumabDrug: PembrolizumabDrug: Gemcitabine/CarboplatinDrug: Methotrexate/Vinblastine/Doxorubicin/CisplatinDrug: Gemcitabine/Cisplatin/NivolumabDrug: ErdafitinibDrug: Paclitaxel/Docetaxel/IfosfamideDrug: GemcitabineDrug: Gemcitabine/Carboplatin/NivolumabDrug: EnfortumabDrug: Sacituzumab
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06204614
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Conditions
- Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 224
- Registration Number
- NCT06203600
- Locations
- 🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06197438
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 650
- Registration Number
- NCT06161025
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳Hubei Cancer Hospital, Wuhan, China
🇰🇷National Cancer Center, Goyang-si, Korea, Republic of
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06161441
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States
🇦🇺St Vincents Hospital, Fitzroy, Victoria, Australia
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT06136988
- Locations
- 🇨🇳
Shandong Tumor Hospital, Jinan, Shandong, China
🇨🇳Tianjin cancer institute &hospital, Tianjin, Tianjin, China
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT06139211
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.